Merveilleux Pharmaceutique (Opc) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 25.00 K
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 83.06%
- Profit Growth -5.63%
- Ebitda -384.49%
- Net Worth 48.87%
- Total Assets -4.45%
About Merveilleux Pharmaceutique (Opc)
Merveilleux Pharmaceutique (Opc) Private Limited (MPOPL) is a registered startup operating as a Company incorporated in India on 26 October 2020 (Four years and three months 16 days old ). Its registered office is in Nashik, Maharashtra, India.
The Company is engaged in the Non-Profit Organizations Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 25.00 K , as per Ministry of Corporate Affairs (MCA) records.
Yogesh Patil serves as a director at the Company.
Company Details
-
Location
Nashik, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85320MH2020OPC348712
-
Company No.
348712
-
Incorporation Date
26 Oct 2020
-
Date of AGM
-
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Merveilleux Pharmaceutique (Opc)?
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yogesh Patil
|
Director | 26-Oct-2020 | Current |
Financial Performance of Merveilleux Pharmaceutique (Opc).
Merveilleux Pharmaceutique (Opc) Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 83.06% increase. The company also saw a slight decrease in profitability, with a 5.63% decrease in profit. The company's net worth Soared by an impressive increase of 48.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Merveilleux Pharmaceutique (Opc)?
Unlock access to Merveilleux Pharmaceutique (Opc)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Merveilleux Neutripharma Private LimitedYogesh Patil is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Merveilleux Pharmaceutique (Opc)?
Merveilleux Pharmaceutique (Opc) has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Merveilleux Pharmaceutique (Opc), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Merveilleux Pharmaceutique (Opc)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.